Cover Image
市場調查報告書

美國的體外診斷(IVD)市場成長機會

Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021

出版商 Frost & Sullivan 商品編碼 509470
出版日期 內容資訊 英文 118 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的體外診斷(IVD)市場成長機會 Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021
出版日期: 2017年05月23日 內容資訊: 英文 118 Pages
簡介

本報告提供美國的體外診斷(IVD)市場調查,提供市場基本結構和各市場區隔的市場趨勢,收益,市場佔有率的分析與預測,成長機會的考察,競爭情形和主要企業等系統性資訊。

第1章 摘要整理

第2章 市場概要

  • 市場定義
  • 市場促進·阻礙因素
  • 考慮PAMA的原因(PAMA)
  • PAMA法規的影響
  • 實施的行動計劃
  • PAMA的影響預測
  • CLSF(臨床檢驗標準費用表)及醫療編碼
  • IVD產業的價值鏈
  • 體外診斷的技術趨勢

第3章 願景與策略:新的成長機會

  • 體外診斷產業的生態系統變化
  • 前3名市場區隔的供應商成長機會
  • 從宏觀轉移到微觀
  • 5大成長機會
  • 成長機會(1)巨量資料的利用
  • 成長機會(2)液態切片(液體細胞診斷)及搭配診斷(CDx)
  • 成長機會(3)分子POC(照護現場)檢驗
  • 成長機會(4)消費者直接耦合型(DTC)檢驗
  • 成長機會(5)藥理基因(PGx)檢驗
  • 美國的體外診斷(IVD)市場預測

第4章 市場預測

  • 體外診斷(IVD)的全體市場:收益預測
  • 收益預測:各市場區隔
  • 收益成長率:各市場區隔
  • 收益率的預測:各市場區隔

第5章 競爭分析

  • 參與企業的策略
  • 競爭矩陣
  • 銷售額分析:各市場區隔
  • 美國市場前13名企業
  • 市場排行榜
  • 主要趨勢
  • 追加的投資機會

第6章 血液學市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第7章 血液凝固市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第8章 照護現場(POT)檢驗市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第9章 分子診斷市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第10章 細胞診斷市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第11章 血糖自我檢測(SMBG)市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第12章 臨床微生物學市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第13章 免疫化學市場區隔的明細

  • 機會與課題
  • 收益預測
  • 市場佔有率分析
  • 關注的產品

第14章 總論

  • 彙整與未來展望
  • 免責聲明

第15章 附錄

目錄
Product Code: K18C-52

US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation

The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of care testing (POCT) and liquid biopsy continue to attract investment opportunities from private equity and venture capitalists. The new government in the United States aims to provide a retail-like experience for healthcare services. As a result, innovative and clinically vetted direct to consumer (DTC) diagnostic testing services are expected to thrive. Partnerships with non-healthcare (HC) companies are expected to empower core diagnostic companies with artificial intelligence (AI) and big data capabilities are on the rise. Given these market trends, it is important to understand the market dynamics to remain competitive and successful in the IVD market in the United States of America.

Research Scope:

The key objectives of this growth opportunity study are to track the changes in the IVD market landscape in the United States for 2016-2021. The study aims to identify growth segments and disruptive companies to invest into. Further, the study provides an in-depth revenue and market share analysis of over 8 segments within the IVD landscape: POCT, tissue diagnostics, self-monitoring blood glucose meter (SMBG), hemostasis, hematology, clinical chemistry, microbiology, immunochemistry, and molecular diagnostics. The study highlights industry challenges, growth drivers, restraints, competitive developments, mergers and acquisition, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA), identifies transforming business models, and makes strategic recommendations to understand the dynamics of the US IVD market. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies and transforming business models, as well as strategic recommendations.

Key Questions this Study will Answer:

  • 1. What are some of the current issues that concern the US IVD industry? How would these impact the different stakeholders in the healthcare landscape?
  • 2. Which are the major segments of growth and why should you invest in them?
  • 3. How to identify partners outside the conventional IVD realm?
  • 4. How can big data support the growth of the IVD industry?
  • 5. What are some of the newer products to watch in 2017 and beyond?
  • 6. Which companies are categorized as early disruptors in this space? Who are the possible candidates to acquire, invest in, and help grow your business?

Table of Contents

1. EXECUTIVE DASHBOARD

  • Purpose of this Experiential Study
  • 5 Step Process to Transformational Growth
  • Scope and Segmentation
  • Market Highlights
  • Strategic Imperatives for Suppliers and Laboratories
  • 6 Big Growth Themes for US IVD Industry
  • Key Questions this Study will Answer

2. GROWTH ENVIRONMENT-MARKET OVERVIEW

  • Market Definition and Segments Covered
  • Market Drivers and Restraints
  • Reasons for Considering PAMA
  • Impact of the PAMA Regulations
  • Proposed Timeline for Implementation
  • Foreseeing the Effects of PAMA
  • CLFS Rate/Code Determination
  • Value Chain of IVD Industry
  • Value Chain of IVD Industry (continued)
  • Value Chain of IVD Industry (continued)
  • Key Disruptive IVD Concepts to Impact Healthcare by 2021
  • Snapshot of Growth Technologies in In-vitro Diagnostics Market

3. VISION AND STRATEGY-EMERGING GROWTH OPPORTUNITIES

  • Transformation in the IVD Industry Ecosystem-2016
  • Growth Opportunities for Suppliers in Top 3 Segments
  • Macro to Micro Visioning
  • 5 Major Growth Opportunities
  • Opportunity 1-Use of Big Data
  • Opportunity 2-Liquid Biopsy and CDx
  • Opportunity 3-Molecular POCT
  • Opportunity 4-Direct-to-Consumer Testing
  • Opportunity 5-PGx Testing
  • Top Predictions for the US IVD Market

4. TOTAL MARKET FORECASTS

  • Total IVD Market-Revenue Forecast
  • Revenue Forecast by Segment
  • Revenue Growth Rate by Segment
  • Percent Revenue Forecast by Segment
  • Overall US IVD Market Share
  • Overall US IVD Market Share Analysis

5. COMPETITIVE ANALYSIS

  • 2016 IVD Market Participant Strategies
  • 2016 IVD Market Participant Strategies (continued)
  • Competitor IVD Matrix
  • Segment Sales Analysis
  • Segment Sales Analysis (continued)
  • Top 13 Companies-US IVD Market
  • Competitor Segment Ranking Matrix
  • Notable Activities
  • Notable Activities (continued)
  • Venture Radar-Additional Investment Opportunities

6. HEMATOLOGY SEGMENT BREAKDOWN

  • Opportunities and Challenges-Hematology
  • Revenue Forecast-Hematology
  • Market Share Analysis-Hematology
  • Products to Watch in 2017

7. HEMOSTASIS SEGMENT BREAKDOWN

  • Opportunities and Challenges-Hemostasis
  • Revenue Forecast-Hemostasis
  • Market Share Analysis-Hemostasis
  • Products to Watch in 2017

8. POCT SEGMENT BREAKDOWN

  • Opportunities and Challenges-POCT
  • Revenue Forecast-POCT
  • Market Share Analysis-POCT
  • Products to Watch in 2017

9. MOLECULAR DIAGNOSTICS SEGMENT BREAKDOWN

  • Opportunities and Challenges-Molecular Diagnostics
  • Revenue Forecast-Molecular Diagnostics
  • Market Share Analysis-Molecular Diagnostics
  • Products to Watch in 2017

10. TISSUE DIAGNOSTICS SEGMENT BREAKDOWN

  • Opportunities and Challenges-Tissue Diagnostics
  • Revenue Forecast-Tissue Diagnostics
  • Market Share Analysis-Tissue Diagnostics
  • Products to Watch in 2017
  • Reimbursement Analysis for Key AP Codes

11. SMBG SEGMENT BREAKDOWN

  • Opportunities and Challenges-SMBG
  • Revenue Forecast-SMBG
  • Market Share Analysis-SMBG
  • Product to Watch in 2017

12. CLINICAL MICROBIOLOGY SEGMENT BREAKDOWN

  • Opportunities and Challenges-Clinical Microbiology
  • Revenue Forecast-Clinical Microbiology
  • Market Share Analysis-Clinical Microbiology
  • Products to Watch in 2017

13. IMMUNOCHEMISTRY SEGMENT BREAKDOWN (INCLUDES REVENUES FOR IMMUNOSSAY, CLINICAL CHEMISTRY, AND URINALYSIS)

  • Opportunities and Challenges-Immunochemistry
  • Revenue Forecast-Immunochemistry
  • Market Share Analysis-Immunochemistry
  • Market Share Analysis (continued)
  • Competitor Customer Coverage

14. LAST WORD

  • Key Conclusions and Future Outlook
  • Legal Disclaimer

15. APPENDIX (CAPITAL PRICING AND INSTALLED BASE)

  • Installed Base and Pricing Analysis-Hematology
  • Installed Base and Pricing Analysis-Hematology (continued)
  • Installed Base and Pricing Analysis-Hemostasis
  • Pricing Analysis-NGS
  • Pricing Analysis-Thermal Cyclers
  • Pricing Analysis-Microarrays
  • Pricing Analysis-Tissue Diagnostics
  • Pricing Analysis-Tissue Diagnostics (continued)
  • Pricing Analysis-Tissue Diagnostics (continued)
  • Pricing Analysis-Tissue Diagnostics (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Immunoassay Systems (continued)
  • Installed Base and Pricing Analysis-Chemistry Analyzers
  • Pricing Analysis-Automated Urine Analyzers
  • Key Abbreviations
  • List of Other Companies Includes
Back to Top